Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Delayed Data from NYSE)

$18.45 USD

18.45
7,100,133

+0.01 (0.05%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $18.45 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (49 out of 250)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bausch Health Q3 Earnings and Revenues Top, Xifaxan Boosts Sales

by Zacks Equity Research

BHC's third-quarter adjusted earnings and revenues beat estimates. The increase in revenue guidance is positive.

Countdown to Teva Pharmaceutical Industries (TEVA) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

by Zacks Equity Research

Evaluate the expected performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Wall Street Analysts Predict a 25.1% Upside in Teva Pharmaceutical Industries (TEVA): Here's What You Should Know

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 25.1% in Teva Pharmaceutical Industries (TEVA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Biotech Stock Roundup: FOLD Settles Patent Dispute, Updates From EDIT & More

by Zacks Equity Research

FOLD and EDIT are in the spotlight following patent dispute settlement news and strategic updates, respectively.

Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Medical Stocks Lagging Teva Pharmaceutical Industries (TEVA) This Year?

by Zacks Equity Research

Here is how Teva Pharmaceutical Industries Ltd. (TEVA) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.

FOLD Stock Rises on Settling Galafold Patent Dispute With Teva

by Zacks Equity Research

Amicus stock gains on reaching a licensing deal with Teva, which ends their Galafold patent lawsuit.

Exelixis Gets Favorable Ruling in Patent Litigation With MSN

by Zacks Equity Research

The Delaware District Court ruled in EXEL's favor, rejecting MSN's challenge to three patents related to cabozantinib.

Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Teva Pharmaceutical Industries (TEVA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Teva Pharmaceutical Industries Ltd. (TEVA) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.

Kinjel Shah headshot

TEVA Stock Rises 72.5% This Year: Time to Buy, Sell or Hold?

by Kinjel Shah

Teva's reasonable valuation, an improving pipeline and the prospect of growth in sales and profits are good enough reasons for those who own the stock to stay invested.

TEVA Q2 Earnings Beat, Generic Business Drives Sales, Stock Up

by Zacks Equity Research

TEVA reports better-than-expected second-quarter results, beating both earnings and sales estimates. Management raises the 2024 financial outlook. The stock climbs 6.2% in response.

Teva Pharmaceutical Industries (TEVA) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Is Teva Pharmaceutical Industries (TEVA) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Hospital Business Recovery to Aid Haemonetics' (HAE) Q1 Earnings

by Zacks Equity Research

Haemonetics' (HAE) first-quarter fiscal 2025 results are likely to reflect the benefits of hemostasis management growth.

Unveiling Teva Pharmaceutical Industries (TEVA) Q2 Outlook: Wall Street Estimates for Key Metrics

by Zacks Equity Research

Evaluate the expected performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Sanofi (SNY) Q2 Earnings Beat, Sales Miss, 2024 View Raised

by Zacks Equity Research

Sanofi (SNY) posts mixed quarterly results, beating estimates for earnings while missing the same for sales. It raises its 2024 earnings growth expectations at CER.

TEVA's Ajovy Meets Goal in Migraine Prevention Study for Kids

by Zacks Equity Research

TEVA achieves the primary efficacy endpoint with statistical significance in the phase III study of its marketed drug, Ajovy, for the prevention of episodic migraine in pediatric patients.

Sundeep Ganoria headshot

3 Generic Drug Stocks to Watch Amid Improving Market Prospects

by Sundeep Ganoria

With the ease in inflationary pressure, the Zacks Medical - Generic Drugs industry is expected to benefit from declining costs. New product launches provide some respite to AMPH, RDY, and TEVA.

AbbVie's (ABBV) Celsius Therapeutics Deal to Boost IBD Presence

by Zacks Equity Research

AbbVie's (ABBV) acquisition of Celsius Therapeutics is set to add the latter's lead pipeline candidate, CEL383, a potential first-in-class TREM1 inhibitor, to ABBV's pipeline.

Here's Why You Should Consider Buying Alvotech (ALVO) Stock

by Zacks Equity Research

Here, we discuss some reasons why buying Alvotech (ALVO) stock now may turn out to be a prudent move.

AbbVie's (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis

by Zacks Equity Research

AbbVie's (ABBV) Skyrizi is now approved for four indications across immune-mediated inflammatory diseases.

AbbVie (ABBV) Buys Global Rights to Novel IBD Candidate

by Zacks Equity Research

AbbVie (ABBV) signs an exclusive global licensing deal with the Chinese company FutureGen to develop FG-M701, a next-generation TL1A antibody, for IBD indications.

TEVA Stock Rises 135% in a Year: What's Driving the Recovery?

by Zacks Equity Research

TEVA expects its newer drugs, Austedo, Uzedy and Ajovy, as well as a stable generics business, to help revive top-line growth in future quarters.

GSK Studies on Depemokimab for Severe Asthma Meet Primary Goals

by Zacks Equity Research

GSK's depemokimab has the potential to become the first ultra-long-acting biologic for severe asthma with a six-month dosing schedule